Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reuterin is a naturally occurring, broad-spectrum antimicrobial compound produced by the probiotic bacterium *Limosilactobacillus reuteri* (formerly *Lactobacillus reuteri*) during the anaerobic fermentation of glycerol. It is not a single substance but a dynamic multi-component system consisting of 3-hydroxypropionaldehyde (3-HPA), its hydrate, its dimer, and acrolein. Reuterin exhibits potent inhibitory activity against a wide range of Gram-positive and Gram-negative bacteria, as well as yeasts, molds, and protozoa. Its mechanism of action involves inducing oxidative stress and inhibiting ribonucleotide reductase, which interferes with DNA synthesis. While primarily studied as a food preservative and a key factor in the probiotic benefits of *L. reuteri*, recent research has highlighted its potential anti-inflammatory and anti-cancer properties, particularly in colorectal cancer models where it may be delivered via engineered probiotic strains.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on reuterin.